We had the honor of taking part in the “Science. Patients. Therapies.” conference on rare diseases, organized by the AGO Alliance Poland foundation at the Medical University of Warsaw in collaboration with the Institute of Molecular Mechanisms and Machines, Polish Academy of Sciences (IMol PAS). The special guest of the event was Prof. Victor Ambros, laureate of the 2024 Nobel Prize in Physiology or Medicine.
Our participation in the conference
Justyna Walczuk — President of the Foundation — delivered a presentation on CFC syndrome associated with MEK2 gene variants and participated in a panel discussion on access to therapies for patients with rare diseases. For the community of patients with MEK2 variants — one of the least visible groups within the RASopathies — every such presence matters. It is thanks to these moments that the medical and scientific community learns that we exist, that we are active, and that we need support in developing therapies.
Aleksandra Świeca presented a scientific poster showcasing the Foundation’s clinical and research activities.


Prof. Victor Ambros’s lecture
In his lecture at the auditorium of the WUM Teaching Center, Prof. Ambros recounted the story of the discovery of microRNA — a new class of RNA molecules that play a key role in the regulation of gene expression. He made this discovery in 1993 during research on the nematode Caenorhabditis elegans; today, microRNAs are known to be involved in the development of many human diseases.
One of the main messages of the lecture was the importance of basic science — research conducted without a direct clinical goal — for later medical breakthroughs. This message is particularly close to our Foundation: every therapy that will one day change the lives of patients with RASopathies begins with someone who patiently asks questions about disease mechanisms.
Prof. Ambros is an ambassador of the AGO Alliance Poland foundation and chair of the Scientific Council of IMol PAS. He has Polish roots — in 2026 he applied for the restoration of his Polish citizenship.
A shared question: why don’t therapies reach patients?
The panel discussions focused on a question we know from our everyday reality: why do so many therapies developed for rare diseases fail to reach the people who need them — and how can we change that? The presence of patient organizations, clinicians, scientists, and healthcare system representatives in this conversation is exactly what is needed if anything is to change.
Patients with ultra-rare diseases, such as CFC syndrome associated with MEK2 variants, are invisible to most of the system — simply because there are so few of us. Conferences that bring together world-class scientists, clinicians, decision-makers, and patient organizations are one of the very few spaces where our voice can be heard by the right people.
We are grateful to have been part of this — and we thank the organizers, the AGO Alliance Poland foundation and IMol PAS, for the invitation and for creating a space in which the voices of patients, clinicians, and scientists sound together.


